Ariel Fernandez

from Wikipedia, the free encyclopedia
Ariel Fernandez

Ariel Fernandez (born April 8, 1957 as Ariel Fernández Stigliano ) is an Argentine - American physical chemist and pharmaceutical scientist.

Education and early career

Fernandez earned a licentiate diplomas in Chemistry (1979) and mathematics (1980) at the Universidad Nacional del Sur in Argentina. He received a doctoral degree from Yale University in 1984 with a thesis on "Structural stability of chemical systems in critical regimes" ( Structural Stability of Chemical Systems at Critical regime) in the group of Oktay Sinanoglu. He published his early publications in association with the Weizmann Institute of Science , Princeton University and the University of California, San Diego . He was a senior scientist in the working group of Nobel Prize winner Manfred Eigen at the Max Planck Institute for Biophysical Chemistry .

Professional career

Fernandez researched and taught at numerous institutes, including a. the University of Miami , the Universidad Nacional del Sur, the Max Planck Institute for Biochemistry , the University of Chicago , the University of Osaka , the Indiana University School of Medicine, the Morgridge Institute for Research, and the National Tsing Hua National University . Until 2011, Fernandez held the Karl F. Hasselmann Professorship for Bioengineering Technology at Rice University . While Fernandez held his endowed chair at Rice University, his biomedical research was funded primarily by the National Institutes of Health (NIH) of the National Institute of General Medical Sciences (NIGMS). He is a member of the National Scientific and Technical Research Council (CONICET) in Argentina. Fernandez is listed as the editor of several journals of the Omics Publishing Group , which however is in disrepute as a so-called “ predatory publisher ”. Fernandez is the Reviewer Editor for Frontiers in Chemistry. He is currently an entrepreneur in a number of self-established pharmacy- related companies such as ProWDSciences, AF Innovation, and Ariel Fernandez Consultancy.

Fernandez developed the concept of the so-called "dehydron", an adhesive structural defect in a water-soluble protein that promotes its own dehydration. A dehydron consists of an intramolecular hydrogen bond that is not sufficiently enveloped or insufficiently protected from water attack from the protein hydration shell. Dehydrons cause so-called "epistructural tension", an interfacial tension around the protein structure, which promotes both protein-protein interactions and protein- ligand associations. The properties of protein dehydrons have an impact on pharmaceutical research , as dehydrons can be the target of highly specific drugs or ligands that, when coupled, lead to better encasing of the dehydron. Dehydrons can therefore be viewed as effective and selective filters for the design of active ingredients , which can be used as a platform for the production of safe drugs by means of so-called “shell technology”. This technology was first used by Fernandez and co-workers to redesign the anti-cancer agent Gleevec to eliminate its potential cardiotoxicity . In a recently granted patent on coating technology, Richard L. Moss and Ariel Fernandez targeted dehydron-rich regions in a specific protein to develop drugs to cure heart failure .

Fernandez has published four books and more than 400 scientific articles.

Awards

Fernandez was named a Camille and Henry Dreyfus Distinguished New Faculty in 1989. In 1991 he received the Camille and Henry Dreyfus Teacher-Scholar Award and in 1995 a Guggenheim scholarship . In 2006 he was made a Fellow of the American Institute for Medical and Biological Engineering.

Publications

Books

  • Ariel Fernández: Transformative Concepts for Drug Design: Target Wrapping. Springer-Verlag, Berlin / Heidelberg 2010, ISBN 978-3-642-11791-6 .
  • Ariel Fernández Stigliano: Biomolecular Interfaces. Springer-Verlag, Berlin / Heidelberg 2015, ISBN 978-3-319-16849-4 .
  • Ariel Fernández: Physics at the Biomolecular Interface. Springer International Publishing AG, Switzerland 2016, ISBN 978-3-319-30851-7 .
  • L. Ridgway Scott and Ariel Fernández: A Mathematical Approach to Protein Biophysics. Springer-Verlag, Switzerland 2017, ISBN 978-3-319-66031-8 .

Trade journals In his Google Scholar profile, the following articles are listed as most cited:

  • A. Fernández, RS Berry. Proteins with H-bond packing defects are highly interactive with lipid bilayers: Implications for amyloidogenesis. In: Proceedings of the National Academy of Sciences . 100, No. 5, 2003, pp. 2391-2396.
  • A. Fernández, J. Kardos, LR Scott, Y. Goto, RS Berry: Structural defects and the diagnosis of amyloidogenic propensity. In: Proceedings of the National Academy of Sciences. 100, No. 11, 2003, pp. 6446-6451.
  • A. Fernández, HA Scheraga: Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. In: Proceedings of the National Academy of Sciences. 100, No. 1, 2003, pp. 113-118.
  • A. Fernández, R. Scott: Dehydron: a structurally encoded signal for protein interaction. In: Biophysical Journal. 85, No. 3, 2003, pp. 1914-1928.
  • A. Fernández, A. Sanguino, Z. Peng, E. Ozturk, J. Chen, A. Crespo, S. Wulf, et al .: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. In: The Journal of Clinical Investigation . 117, No. 12, 2007, pp. 4044-4054.

Patents granted

  • U.S. 8,466,154
  • U.S. 9,051,387

Web links

Individual evidence

  1. ↑ a b c d e Ariel Fernandez CV and Biographical Narrative. academia.edu, accessed on August 30, 2016 .
  2. ^ Ariel Fernandez: Structural Stability of Chemical Systems at Critical Regimes (Dissipative Structures, Potential Energy Surfaces) . In: Dissertation Abstracts International . 1984 ( proquest.com ).
  3. ^ "Administration and faculty" (PDF), Catalog 2010–2011. ( Memento of the original from November 25, 2014 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. Rice University, accessed February 2, 2014. @1@ 2Template: Webachiv / IABot / www.rice.edu
  4. ↑ Grantome: Search. Retrieved January 28, 2020 (English).
  5. ↑ Comunicación - Conicet.
  6. ↑ Editorial Board Bioengineering & Biomedical Science.
  7. ^ "Editors - Metabolomics Journals - Editorial Board"
  8. ^ "Editors - Pharmacogenomics Journals - Editorial Board"
  9. ^ Michael Stratford: 'Predatory' Online Journals Lure Scholars Who Are Eager to Publish . Chronicle.com. March 4, 2012. Retrieved October 2, 2012.
  10. ^ "Ariel Fernandez Editor for Frontiers in Chemistry"
  11. ↑ Ariel Fernández, Ridgway Scott: Dehydron: a structurally encoded signal for protein interaction . In: Biophysical Journal . tape 85 , no. 3 , September 1, 2003, ISSN  0006-3495 , p. 1914–1928 , doi : 10.1016 / S0006-3495 (03) 74619-0 , PMID 12944304 , PMC 1303363 (free full text).
  12. ^ Ariel Fernández, L. Ridgway Scott: Adherence of packing defects in soluble proteins . In: Physical Review Letters . tape 91 , no. 1 , July 4, 2003, ISSN  0031-9007 , p. 018102 , doi : 10.1103 / PhysRevLett.91.018102 , PMID 12906578 .
  13. ^ S. Koppes: Discovery of new sticky force that binds proteins could lead to better drug design. news.uchicago.edu, July 2, 2003, accessed August 30, 2016 .
  14. ↑ Ariel Fernández: Epistructural tension promotes protein associations . In: Physical Review Letters . tape 108 , no. 18 , May 4, 2012, ISSN  1079-7114 , p. 188102 , doi : 10.1103 / PhysRevLett.108.188102 , PMID 22681121 .
  15. ↑ Don Monroe: Focus: Proteins Hook up Where Water Allows . In: Physics . tape 5 , May 4, 2012 ( aps.org ).
  16. ↑ Sarah Crunkhorn: Anticancer drugs: Redesigning kinase inhibitors . In: Nature Reviews Drug Discovery . tape 7 , no. 2 , p. 120-121 , doi : 10.1038 / nrd2524 .
  17. ^ J. Boyd: Drug design: New book introduces fresh approach. news.rice.edu, April 28, 2010, accessed August 30, 2016 .
  18. ↑ George D. Demetri: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy . In: Journal of Clinical Investigation . tape 117 , no. 12 , December 3, 2007, pp. 3650–3653 , doi : 10.1172 / JCI34252 , PMC 2096446 (free full text).
  19. ^ W. Dunham: Reworked Gleevec curbs heart-related complication . In: Reuters . December 3, 2007 ( reuters.com ).
  20. ↑ Richard L. Moss, Ariel Fernandez: Invention: Treating Heart Failure by Inhibiting Myosin Interaction with a Regulatory Myosin Binding Protein (= US patent No. 9,051,387 ) Wisconsin Alumni Research Foundation ( warf.org ).
  21. ↑ Thomson Reuters ResearcherID Ariel Fernandez
  22. ↑ Ariel Fernández.
  23. ^ College of Fellows.
  24. ^ Ariel Fernandez - Google Scholar Citations.
personal data
SURNAME Fernandez, Ariel
ALTERNATIVE NAMES Stigliano, Ariel Fernández (maiden name)
BRIEF DESCRIPTION Argentine-American physical chemist and pharmaceutical scientist
DATE OF BIRTH April 8, 1957